×
About 26,695 results

ALLMedicine™ Renal Cell Carcinoma Center

Research & Reviews  9,050 results

Special issue "The advance of solid tumor research in China": Multi-omics analysis base...
https://doi.org/10.1002/ijc.34121
International Journal of Cancer; Tian X, Wang Y et. al.

May 18th, 2022 - In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise syst...

Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic...
https://doi.org/10.1001/jamanetworkopen.2022.12347
JAMA Network Open; Chakiryan NH, Gore LR et. al.

May 17th, 2022 - Level I evidence has failed to demonstrate an overall survival (OS) advantage for cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma (ccRCC) in the modern era, which is at odds with observational studies reportin...

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in C...
https://doi.org/10.1001/jamanetworkopen.2022.12327
JAMA Network Open; Ahmed N, Vengalasetti Y et. al.

May 17th, 2022 - Adjuvant drugs are used to reduce the risk of tumor recurrence in patients with cancer who are successfully treated with first-line therapy. The same drugs used in the metastatic or first-line setting are often used in the adjuvant setting, and al...

Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With A...
https://doi.org/10.46883/2022.25920957
Oncology (Williston Park, N.Y.); Panian J, Pan E et. al.

May 17th, 2022 - A Mexican woman, aged 60 years, presented with fevers and abdominal pain. She had initially presented to an outside emergency department with weakness, malaise, nausea, vomiting, tachycardia to 110s, and fever to 102 °F. Her medical history was re...

Clear Cell Renal Cell Carcinoma with Immunotherapy Effect Mimicking Xanthogranulomatous...
https://doi.org/10.1177/10668969221101873
International Journal of Surgical Pathology; Wang Y, Ganesan S et. al.

May 17th, 2022 - Renal cell carcinoma is now increasingly treated with checkpoint inhibitor therapy, predominantly in the metastatic setting or occasionally in the adjuvant setting; however, there is little published histopathology data demonstrating the post-ther...

see more →

Guidelines  23 results

ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clini...
https://doi.org/10.1016/j.jacr.2022.02.015
Journal of the American College of Radiology : JACR; , Purysko AS et. al.

May 14th, 2022 - Renal cell carcinoma (RCC) accounts for most malignant renal tumors and is considered the most lethal of all urologic cancers. For follow-up of patients with treated or untreated RCC and those with neoplasms suspected to represent RCC, radiologic ...

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0001
Journal of the National Comprehensive Cancer Network : JN... Motzer RJ, Jonasch E et. al.

Jan 7th, 2022 - The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor hist...

Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523177/
Journal of Kidney Cancer and VHL; Lin J

Oct 13th, 2021 - Advance diagnostic and treatment modalities have improved outcomes for renal cell carcinoma (RCC) patients, but the prognosis for those with metastatic disease (mRCC) remains poor. As given metastatic distribution is critical in guiding treatment ...

Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing
https://pubmed.ncbi.nlm.nih.gov/34654685/
European Urology Oncology; Truong H

Oct 12th, 2021 - Despite guidelines recommending genetic counseling for patients with early-onset renal cell carcinoma (RCC), studies interrogating the spectrum of germline mutations and clinical associations in patients with early-onset RCC are lacking.

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and ...
https://doi.org/10.1016/j.annonc.2021.09.014
Annals of Oncology : Official Journal of the European Soc... Powles T, Albiges L et. al.

Oct 2nd, 2021 - ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.|2021|Powles T,Albiges L,Bex A,Grünwald V,Porta C,|drug therapy,drug therapy,

see more →

Drugs  42 results see all →

Clinicaltrials.gov  371 results

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
https://clinicaltrials.gov/ct2/show/NCT04923178

May 13th, 2022 - Background: Rare histological variants of the GU tract include bladder/urachal adenocarcinoma, squamous cell carcinoma, and small cell carcinoma; variants of urothelial carcinoma including plasmacytoid, sarcomatoid; renal tumors including sarcomat...

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
https://clinicaltrials.gov/ct2/show/NCT00050752

May 13th, 2022 - Background: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma. HLRCC is caused by mutations i...

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
https://clinicaltrials.gov/ct2/show/NCT01354431

May 12th, 2022 - The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04028245

May 11th, 2022 - Patients with localized and non-metastatic Renal Cell Carcinoma (RCC) represent an "at-need" population who would benefit from immunotherapy earlier in their disease course with a programmed cell death protein 1(PD-1) therapy combined with a secon...

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
https://clinicaltrials.gov/ct2/show/NCT02853344

May 11th, 2022 - The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC). There will be two cohorts in this study: Cohort A will consist of participants with clear cell (...

see more →

News  1,188 results

FDA Rejects More China Drugs; Clue to Uterine Ca Disparity; Cancer-Vax Controversy
https://www.medpagetoday.com/hematologyoncology/othercancers/98587

May 6th, 2022 - China-based Hutchmed announced receipt of a complete response letter from the FDA, stating that the agency cannot approve the tyrosine kinase inhibitor surufatinib for advanced neuroendocrine tumors without support from a multiregional clinical tr...

Ongoing Clinical Trials in the Neoadjuvant Setting in RCC
https://www.onclive.com/view/ongoing-clinical-trials-in-the-neoadjuvant-setting-in-rcc

May 4th, 2022 - Tian Zhang, MD: Dr Barata, can you provide a brief overview of some ongoing neoadjuvant therapy trials? In particular, we saw some data from one of the first IO [immunotherapy]/VEGF combination trials to report out, avelumab and axitinib, at ASCO ...

Renal Cell Carcinoma: Future Directions in Care
https://www.onclive.com/view/renal-cell-carcinoma-future-directions-in-care

May 2nd, 2022 - Transcript: Robert J. Motzer, MD: Two last quick points for you. Cabozantinib is 1 of our main go-to drugs for RCC [renal cell carcinoma]. It’s been proposed to be particularly effective for bone metastases, right? There were recent data for cabo...

Adverse Events in IO-IO Combination Treatment Regimens for Advanced RCC
https://www.onclive.com/view/adverse-events-in-io-io-combination-treatment-regimens-for-advanced-rcc

May 2nd, 2022 - Arnab Basu, MD: In your experience, what are some of the commonly observed adverse events in this IO [immunotherapy]/IO combination therapy regimen, and how do you manage those? Shawnta Anakwah, MD: Typically, the ones that I’ve seen have been ra...

Microbiota Modulation Offers Hope of Expanding the Benefits of Immunotherapy
https://www.onclive.com/view/microbiota-modulation-offers-hope-of-expanding-the-benefits-of-immunotherapy

Apr 28th, 2022 - Although the microorganisms colonizing our bodies have long been linked to human health and various disease states, an understanding of the potential impact of the microbiota on cancer has just begun to emerge in the past 20 years. Novel strategie...

see more →

Patient Education  4 results see all →